Clinical Trial Update: STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for STRIDES investigating an investigational drug for Spinocerebellar Ataxia Type 3 has been terminated after Phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinocerebellar Ataxia Type 3

Drugs mentioned

• STRIDES (investigational drug)

Snippet

Sponsor: Seelos Therapeutics, Inc. | Conditions: Spinocerebellar Ataxia Type 3 | Phase 2, Phase 3 | Status: TERMINATED